An Open-Label Study Of Lamictal In Neurotic Excoriation

Completed · Phase 2

Conditions studied: Neurotic Disorders, Obsessive-Compulsive Disorder

In brief

The goal of the proposed study is to evaluate the efficacy and safety of Lamictal in neurotic excoriation. Twenty subjects with neurotic excoriation will receive 12 weeks of open-label treatment with Lamictal. The hypothesis to be tested is that Lamictal will be effective and well tolerated in patients with neurotic excoriation. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Key facts

Study ID

NCT00269594

Run by

University of Minnesota

People needed

25

Starts

2006-01-01

Expected to finish

2006-09-01

Last updated by the study team

2007-04-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• men and women age 18-65
• current diagnosis of neurotic excoriation

You may not qualify if…

• unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination
• history of seizures
• myocardial infarction within 6 months
• current pregnancy or lactation, or inadequate contraception in women of childbearing potential
• a need for medication other than Lamictal with possible psychotropic effects or unfavorable interactions with Lamictal
• clinically significant suicidality
• lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder
• current or recent (past 3 months) DSM-IV substance abuse or dependence
• illegal substance use within 2 weeks of study initiation
• initiation of psychotherapy or behavior therapy from a mental health professional within 3 months prior to study baseline
• previous treatment with Lamictal
• treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline
• current treatment with an anti-epileptic medication and
• patients who have previously been diagnosed with a medical condition that cause skin itchiness (e.g. liver, kidney, and blood diseases, etopic allergies)

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.